Health ❯ Healthcare ❯ Patient Care

Oncology

Survival Rates Cancer Treatment Chemotherapy Treatment Outcomes Leukemia Medication Access Metastatic Cancer Support Networks Bone Marrow Transplant Support Systems Treatment Experiences Solid Tumors Cancer Patient Support Neurosurgery Prostate Cancer Treatment Delays in Treatment Medications Blood Components Palliative Care Tumor Removal Surgical Procedures Tumor Markers Advanced Lung Cancer Combination Therapy Bladder Cancer Management Dietary Management in Oncology Acute Lymphoblastic Leukemia Aggressive Lymphoma Cancer Cachexia Oncohematology Recurrent Cancer Relapsed Multiple Myeloma Muscle-Invasive Bladder Cancer Exercise Programs Child Health Relapsed/Refractory Multiple Myeloma Communication Strategies Oncology Unit Contamination Urologic Oncology Advanced Melanoma Advanced Cancer Cancer Support Childhood Cancer Breast Cancer Treatment Advanced Breast Cancer Cancer Diagnosis Tumor Treatment Metastatic Breast Cancer Precision Medicine Access to Treatment Hormone Receptor Positive Breast Cancer

PROTEXI Vaccine Redirects COVID‑19 Immune Memory to Target Tumors

A peer‑reviewed preclinical study reports stronger tumor‑specific T‑cell responses and has prompted plans for a first‑in‑human sarcoma trial.

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Most Detailed Prostate Cancer Cell Atlas Yet Charts Earliest Disease Signals

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Quitting After Cancer Diagnosis Linked to Higher Two-Year Survival, JNCCN Study Finds

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors